The demand for Dermatological Drugs in Australia has been on the rise in recent years due to various factors.
Customer preferences: Customers in Australia have become more health-conscious and are willing to spend on skincare and dermatological treatments. The aging population is also contributing to the growth of the market as they seek treatments for age-related skin conditions. Additionally, the rise of social media and the beauty industry has increased the demand for cosmetic dermatology treatments.
Trends in the market: One of the major trends in the Dermatological Drugs market in Australia is the shift towards natural and organic products. Customers are becoming more aware of the harmful effects of synthetic chemicals and are opting for products with natural ingredients. Another trend is the rise of telemedicine and online consultations, which have become popular during the COVID-19 pandemic.
Local special circumstances: Australia has a high incidence of skin cancer, which is driving the demand for dermatological treatments. The country has one of the highest rates of skin cancer in the world, and this has led to a focus on prevention and early detection. The government has also implemented various public health campaigns to raise awareness about the importance of sun protection.
Underlying macroeconomic factors: The Australian economy has been growing steadily in recent years, which has led to an increase in disposable income. This has allowed customers to spend more on healthcare and cosmetic treatments. Additionally, the government has a strong healthcare system, which provides access to affordable healthcare for all citizens. This has contributed to the growth of the Dermatological Drugs market by increasing accessibility to treatments.In conclusion, the Dermatological Drugs market in Australia is driven by customer preferences for natural and organic products, the rise of telemedicine, the high incidence of skin cancer, and the growing economy. These factors are expected to continue to drive the growth of the market in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
